Video

Dr. Majhail on the Importance of Utilizing Social Media in Oncology

Navneet Majhail, MD, MS, discusses the importance of utilizing social media in oncology.

Navneet Majhail, MD, MS, director, Blood and Marrow Transplant Program, Cleveland Clinic, staff physician, Department of Hematology and Oncology, Taussig Cancer Institute, professor of medicine, Cleveland Clinic Lerner College of Medicine, discusses the importance of utilizing social media in oncology.

During the 47th Annual Meeting of the EBMT, Majhail gave a series of presentations as part of the young ambassadors session on the importance of social media in the realm of stem cell transplant and cellular therapy. In this setting, social media can offer physicians insight into recently published data, the chance to participate in interactive discussions with colleagues, and networking opportunities, Majhail says. Additionally, some of the advantages of certain treatment approaches and how they could be applied to clinical practice are subject to professional commentary on social media, explains Majhail.

Additionally, many patients are active on social media as a way to educate themselves about their condition, seek peer support, or raise advocacy awareness, Majhail says. Learning about or interacting with a patient in a more relaxed environment outside of the clinic, such as on social media, can be dually beneficial to the patient and physician, concludes Majhail.

Related Videos
David C. Fisher, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss factors to help determine intensive chemotherapy fitness in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss the diagnosis and prevalence of secondary acute myeloid leukemia.